RLAY news

Relay Therapeutics reported $849 million in cash and announced ongoing Phase 3 trial enrollment progress for breast cancer. The company also provided an update regarding an upcoming ASH conference presentation and the hiring of a new executive to lead commercial preparations.

Relay Therapeutics amended its certificate of incorporation to increase total authorized capital stock from an unstated prior amount to 460 million shares, comprising 450 million common shares and 10 million preferred shares. The amendment provides the company flexibility for future financing, equit…

Relay Therapeutics launched an underwritten public offering of approximately 22.9 million shares of common stock with an option for underwriters to purchase an additional 3.4 million shares. The offering is expected to raise approximately $996 million in gross proceeds, providing capital for the bio…

Relay announced initial Phase 2 data showing zovegalisib achieved a 60% volumetric response rate in PIK3CA-driven vascular anomalies patients at 12 weeks, with 89% investigator-reported clinical improvement and a favorable safety profile supporting chronic dosing. The positive efficacy and tolerabil…